Published in Am J Respir Cell Mol Biol on December 18, 2008
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med (2014) 3.29
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob Agents Chemother (2012) 0.86
Role of PPE18 protein in intracellular survival and pathogenicity of Mycobacterium tuberculosis in mice. PLoS One (2012) 0.85
Expression of the leptin receptor outside of bone marrow-derived cells regulates tuberculosis control and lung macrophage MHC expression. J Immunol (2011) 0.79
Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. Mol Ther Nucleic Acids (2012) 0.78
IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis. Tuberculosis (Edinb) (2013) 0.77
Intratracheal Bleomycin Aerosolization: The Best Route of Administration for a Scalable and Homogeneous Pulmonary Fibrosis Rat Model? Biomed Res Int (2015) 0.76
Platelet Activating Factor Receptor Activation Improves siRNA Uptake and RNAi Responses in Well-differentiated Airway Epithelia. Mol Ther Nucleic Acids (2014) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. Kona (2015) 0.75
Burkholderia pseudomallei-derived miR-3473 enhances NF-κB via targeting TRAF3 and is associated with different inflammatory responses compared to Burkholderia thailandensis in murine macrophages. BMC Microbiol (2016) 0.75
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med (1993) 17.01
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology (1995) 3.45
Lymphotactin: a cytokine that represents a new class of chemokine. Science (1994) 2.74
Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med (2006) 2.63
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med (2005) 2.55
The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol (1995) 2.21
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res (2007) 2.06
Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A (2008) 2.06
Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther (2008) 2.02
Chemokine response in mice infected with Mycobacterium tuberculosis. Infect Immun (1995) 1.99
Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun (2000) 1.92
Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect Immun (2001) 1.80
Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem (2003) 1.65
Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol (2003) 1.63
Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol (2005) 1.58
Molecular cloning and functional characterization of human lymphotactin. J Immunol (1995) 1.50
Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem (1999) 1.44
Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm (2005) 1.39
In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol (2005) 1.32
Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect Immun (2004) 1.31
Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.19
Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm (2008) 1.07
XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability. J Leukoc Biol (2007) 1.05
Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis. J Immunol (2008) 1.02
Retracted Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J Immunol (2006) 0.94
Induction of C chemokine XCL1 (lymphotactin/single C motif-1 alpha/activation-induced, T cell-derived and chemokine-related cytokine) expression by HIV-1 Tat protein. J Immunol (2004) 0.93
Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum (2003) 0.93
RNA interference: an emerging generation of biologicals. Biotechnol J (2008) 0.89
The C-class chemokine lymphotactin costimulates the apoptosis of human CD4(+) T cells. Blood (2001) 0.87
Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity. J Immunol Methods (2005) 0.86
Airway epithelium-derived transforming growth factor-beta is a regulator of fibroblast proliferation in both fibrotic and normal subjects. Clin Exp Allergy (2008) 0.85
Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am J Pathol (2001) 0.85
Visualization of the transgene distribution according to the administration route allows prediction of the transfection efficacy and validation of the results obtained. Gene Ther (2002) 0.81
RNAi therapeutics: can siRNAs conquer SARS? Gene Ther (2006) 0.77
Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med (2004) 6.27
Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol (2008) 4.31
Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol (2002) 3.74
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother (2005) 3.16
Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution--reproducibility study. Radiology (2006) 2.84
Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med (2003) 2.82
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol (2007) 2.66
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother (2003) 2.30
Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J Immunol (2003) 2.25
Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun (2003) 2.06
In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol (2002) 2.04
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A (2009) 1.86
Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun (2003) 1.81
Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun (2006) 1.75
The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J Immunol (2007) 1.61
Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol (2005) 1.58
Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol (2005) 1.56
NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol (2003) 1.49
Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis (2013) 1.49
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb) (2008) 1.46
Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb) (2009) 1.45
CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol (2002) 1.42
Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-beta. J Clin Invest (2007) 1.41
Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol (2008) 1.39
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother (2010) 1.37
Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-Binding: requirement for establishing chronic persistent infection. PLoS Pathog (2009) 1.37
Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol (2010) 1.35
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 1.33
Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol (2010) 1.33
Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) (2011) 1.28
Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. Tuberculosis (Edinb) (2006) 1.28
Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol (2008) 1.27
Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson (2014) 1.27
Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol (2008) 1.26
Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol (2010) 1.26
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis. Immunology (2003) 1.26
Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol (2012) 1.24
Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb) (2009) 1.23
Cigarette smoke increases susceptibility to tuberculosis--evidence from in vivo and in vitro models. J Infect Dis (2011) 1.21
Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) (2009) 1.20
Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.19
Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.18
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.17
Sulfolipid deficiency does not affect the virulence of Mycobacterium tuberculosis H37Rv in mice and guinea pigs. Infect Immun (2003) 1.17
Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol. Infect Immun (2006) 1.16
Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet (2003) 1.15
Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol (2011) 1.15
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol (2007) 1.14
Localized immunosuppressive environment in the foreign body response to implanted biomaterials. Am J Pathol (2009) 1.12
The principal sigma factor sigA mediates enhanced growth of Mycobacterium tuberculosis in vivo. Mol Microbiol (2004) 1.12
Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection. PLoS One (2013) 1.10
Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis (Edinb) (2011) 1.09
Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.08
Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberculosis (Edinb) (2007) 1.08
Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. Am J Respir Cell Mol Biol (2008) 1.08
Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine (2005) 1.06
Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population. Infect Immun (2005) 1.05
XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability. J Leukoc Biol (2007) 1.05
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother (2010) 1.05
Enhanced macrophage activity in granulomatous lesions of immune mice challenged with Mycobacterium tuberculosis. J Immunol (2006) 1.03
Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis. J Immunol (2008) 1.02
Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis. PLoS One (2011) 1.02
Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect Immun (2005) 1.02
Statistical limitations to the Cornell model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb) (2004) 1.02
Old mice express a transient early resistance to pulmonary tuberculosis that is mediated by CD8 T cells. Infect Immun (2002) 1.01
SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infect Immun (2003) 0.99
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2008) 0.99
HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol (2012) 0.98
A limited antigen-specific cellular response is sufficient for the early control of Mycobacterium tuberculosis in the lung but is insufficient for long-term survival. Infect Immun (2004) 0.97
The study of Mycobacterium leprae infection in interferon-gamma gene--disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J Infect Dis (2002) 0.96
Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cell Immunol (2002) 0.96
Animal models of mycobacteria infection. Curr Protoc Immunol (2011) 0.95
Mycobacteria lacking the RD1 region do not induce necrosis in the lungs of mice lacking interferon-gamma. Immunology (2006) 0.95
Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 0.95
Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. Retrovirology (2014) 0.93
Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis (Edinb) (2010) 0.93
The expression of early resistance to an infection with Mycobacterium tuberculosis by old mice is dependent on IFN type II (IFN-gamma) but not IFN type I. Mech Ageing Dev (2004) 0.92
Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology (2006) 0.92
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 0.92
Mycobacterium tuberculosis nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity. PLoS Pathog (2013) 0.92
In vivo adaptation of the Wayne model of latent tuberculosis. Infect Immun (2007) 0.92
T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb) (2011) 0.92